The importance such studies is underlined by the fact that mutational status in metastatic colorectal cancer is already an approved clinical tool for treatment with epidermal growth factor receptor monoclonal antibodies, cetuximab or panitumumab; as mutant KRAS has been established as a predictor of resistance to the treatment [24], [25]. This evidence concerns the gene EGFR and metastatic colorectal cancer.